Skip to main content
. 2022 Nov 25;14(12):2598. doi: 10.3390/pharmaceutics14122598

Table 4.

Summary of the analysis of the studies’ methodologies.

References Items Where Information Was Present Information Not Present or
Not Reported
Total Applicable Items Percentage of
Reported Items
Quality Rating
Appiah-Kusi et al., 2020 [10] 9 5 14 64% Fair
Ben-Menachem et al., 2020 [11] 10 4 14 71% Fair
Efron et al., 2020 [12] 10 4 14 71% Fair
Freeman et al., 2020 [13] 14 0 14 100% Good
Meneses-Gaya et al., 2020 [14] 11 3 14 79% Good
Thiele et al., 2020 [15] 9 5 14 64% Fair
VanLandingham et al., 2020 [16] 7 7 14 50% Fair
Crippa et al., 2021 [17] 14 0 14 100% Good
De Almeida et al., 2021 [18] 11 3 14 79% Good
Leweke et al., 2021 [19] 9 5 14 64% Fair
Mongeau-Pérusse et al., 2021 [20] 11 3 14 79% Good
Atieh et al., 2022 [21] 10 1 14 71% Good

Quality Rating: Poor <50%, Fair 50–75%, Good >75% (See Table S1).